Table 2.
Comparison of cerebral small vessel disease (CSVD) features and CSVD burden scores between outcome groups
| Full cohort, number (%) (n=288) | ||||
| Entire cohort (n=288) |
Favourable outcome (n=127) |
Unfavourable outcome (n=161) | P value | |
| Presence of lacunes | 26 (9) | 8 (6) | 18 (11) | 0.21 |
| Lobar lacunes | 9 (3) | 4 (3) | 5 (3) | 1.00 |
| Deep lacunes | 17 (6) | 4 (3) | 13 (8) | 0.13 |
| Presence of CMBs | 118 (41) | 45 (35) | 73 (45) | 0.09 |
| Deep CMBs | 0.06 | |||
| 0 | 214 (74) | 102 (80) | 112 (70) | |
| 1 | 31 (11） | 16 (13） | 15 (9） | |
| 2–4 | 20 (7） | 6 (5） | 14 (9） | |
| 5–10 | 22 (8） | 7 (6） | 15 (9） | |
| >10 | 5 (2） | 0 (0） | 5 (3） | |
| Lobar CMBs | 0.16 | |||
| 0 | 196 (68) | 92 (72) | 104 (65) | |
| 1 | 31 (11) | 16 (13) | 15 (9) | |
| 2–4 | 20 (7) | 6 (5) | 14 (9) | |
| 5–10 | 30 (10) | 11 (9) | 19 (12) | |
| >10 | 11 (4) | 2 (2) | 9 (6) | |
| Total CMBs | 0.19 | |||
| 0 | 170 (59) | 82 (65) | 88 (55) | |
| 1 | 32 (11) | 16 (13) | 16 (10) | |
| 2–4 | 25 (11) | 10 (8) | 15 (9) | |
| 5–10 | 39 (14) | 13 (10) | 26 (16) | |
| >10 | 22 (8) | 6 (5) | 16 (10) | |
| CMBs≥5 | 61 (21) | 19 (15) | 42 (26) | 0.03 |
| Number of EPVS in BG | 0.08 | |||
| 0 | 24 (8) | 14 (11) | 10 (6) | |
| 1–10 | 98 (34) | 50 (39) | 48 (30) | |
| 11–20 | 68 (24) | 30 (24) | 38 (24) | |
| 21–40 | 74 (26) | 26 (21) | 48 (30) | |
| >40 | 24 (8) | 7 (6) | 17 (11) | |
| Number of EPVS in CSO | 0.59 | |||
| 0 | 41 (14) | 19 (15) | 22 (14) | |
| 1–10 | 61 (21) | 27 (21) | 34 (21) | |
| 11–20 | 50 (17) | 17 (13) | 33 (21) | |
| 21–40 | 74 (26) | 36 (28) | 38 (24) | |
| >40 | 62 (22) | 28 (22) | 34 (21) | |
| Severe EPVS in BG | 166 (58) | 63 (50) | 103 (64) | 0.02 |
| Deep Fazekas score | <0.001 | |||
| 0 | 82 (29) | 49 (39) | 33 (21) | |
| 1 | 129 (45) | 62 (49) | 67 (42) | |
| 2 | 60 (21) | 13 (10) | 47 (29) | |
| 3 | 17 (6) | 3 (2) | 14 (9) | |
| Periventricular Fazekas score | <0.001 | |||
| 0 | 6 (2) | 6 (5) | 0 | |
| 1 | 133 (46) | 79 (62) | 54 (34) | |
| 2 | 98 (34) | 33 (26) | 65 (40) | |
| 3 | 51 (18) | 9 (7) | 42 (26) | |
| Total Fazekas score | <0.001 | |||
| 0 | 6 (2) | 6 (5) | 0 | |
| 1 | 64 (22) | 36 (28) | 28 (17) | |
| 2 | 71 (25) | 47 (37) | 24 (15) | |
| 3 | 65 (23) | 22 (17) | 43 (27) | |
| 4 | 46 (16) | 10 (8) | 36 (22) | |
| 5 | 19 (7) | 3 (2) | 16 (10) | |
| 6 | 17 (6) | 3 (2) | 14 (9) | |
| Severe WMH | 147 (51) | 38 (30) | 109 (68) | <0.001 |
| Presence of cSS | 38 (13) | 9 (7) | 27 (17) | 0.02 |
| Focal (≤3 sulci) | 36 (13) | 9 (18) | 25 (16) | |
| Disseminated (≥4 sulci) | 2 (1) | 0 | 2 (1) | |
| CSVD score | <0.001 | |||
| 0 | 56 (19) | 39 (31) | 17 (11) | |
| 1 | 80 (27) | 42 (33) | 38 (24) | |
| 2 | 89 (31) | 28 (22) | 59 (37) | |
| 3 | 57 (20) | 16 (13) | 41 (25) | |
| 4 | 8 (3) | 2 (1) | 6 (3) | |
| CAA score | <0.001 | |||
| 0 | 98 (34) | 66 (52) | 32 (20) | |
| 1 | 82 (29) | 29 (23) | 53 (33) | |
| 2 | 53 (18) | 20 (16) | 33 (21) | |
| 3 | 32 (11) | 9 (7) | 23 (14) | |
| 4 | 21 (7) | 3 (2) | 18 (11) | |
| 5 | 2 (1) | 0 | 2 (1) | |
| 6 | 0 | 0 | 0 | |
| Modified CSVD score | <0.001 | |||
| 0 | 60 (21) | 43 (34) | 17 (11) | |
| 1 | 91 (31) | 46 (36) | 44 (27) | |
| 2 | 84 (29) | 25 (20) | 58 (36) | |
| 3 | 41 (14) | 11 (9) | 30 (19) | |
| 4 | 13 (5) | 2 (1) | 11 (7) | |
| 5 | 1 (0) | 0 (0) | 1 (0) | |
Severe EPVS=grade 3 (21–40) and 4 (>40).
BG, basal ganglia; CAA, cerebral amyloid angiopathy; CMB, cerebral microbleeds; CSO, centrum semiovale; cSS, cortical superficial siderosis; CSVD, cerebral small vessel disease; EPVS, enlarged perivascular spaces; WMH, white matter hyperintensities.